These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23824381)

  • 1. Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
    Vermehren A; Welsch C; Elsler U; Vermehren J; Herrmann E; Sarrazin C; von Wagner M; Susser S; Hofmann WP; Kronenberger B; Zeuzem S; Mihm U
    Antivir Ther; 2013; 18(6):803-11. PubMed ID: 23824381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
    Mihm U; Grigorian N; Welsch C; Herrmann E; Kronenberger B; Teuber G; von Wagner M; Hofmann WP; Albrecht M; Lengauer T; Zeuzem S; Sarrazin C
    Antivir Ther; 2006; 11(4):507-19. PubMed ID: 16856625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
    Castelain S; Bonte D; Penin F; François C; Capron D; Dedeurwaerder S; Zawadzki P; Morel V; Wychowski C; Duverlie G
    J Med Virol; 2007 Feb; 79(2):144-54. PubMed ID: 17177298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
    Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
    Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
    De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
    J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
    Berg T; Kronenberger B; Hinrichsen H; Gerlach T; Buggisch P; Herrmann E; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1359-67. PubMed ID: 12774015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
    Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
    Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
    Jin YJ; Park YK; Yun GJ; Lee HC; Jeong SH; Kim GM; Lim YS; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2010 Jun; 16(2):158-67. PubMed ID: 20606500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
    Palabıyıkoğlu M; Ormeci N; Ekiz F; Beyler AR; Erdem H; Dökmeci A; Ozkan H; Köklü S; Coban S
    Hepatogastroenterology; 2012 Sep; 59(118):1911-4. PubMed ID: 22819912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
    Ciancio A; Picciotto A; Giordanino C; Smedile A; Tabone M; Manca A; Marenco G; Garbagnoli P; Andreoni M; Cariti G; Calleri G; Sartori M; Cusumano S; Grasso A; Rizzi R; Gallo M; Basso M; Anselmo M; Percario G; Ciccone G; Rizzetto M; Saracco G
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1079-86. PubMed ID: 16984502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.